Forvisirvat Drug Asset Due Diligence Report 2026

This Forvisirvat Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.

Decision date: 18 September 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.

Phase 2

Highest phase

Registered trials

Result records

Matched deals

Executive recommendation: CONDITIONAL GO

Decision memo

Advance with milestone-based economics while efficacy durability, safety differentiation, patent scope, and market positioning are validated.

The central underwriting question is whether Forvisirvat can convert its Small molecule drug profile and SIRT6 biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.

1. Asset identity and development status

Asset	Forvisirvat (query alias: Forvisirvat)
Modality / target	Small molecule drug; SIRT6; SIRT6 agonists, Epigenetic drug
Highest global status	Phase 2
Originator	Sirtsei Pharmaceuticals, Inc.
Active developers	Sirtsei Pharmaceuticals, Inc.

The MCP disease footprint includes Depressive Disorder, Major. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.

2. Clinical program: design and endpoint audit

Registry	Phase	Status	Enrollment	Lead primary endpoint
NCT06570369	Phase 1	Completed	26	Primary endpoint not disclosed in English source
NCT06254612	Phase 2	Completed	497	Primary endpoint not disclosed in English source
NCT04510298	Phase 1	Completed	27	Primary endpoint not disclosed in English source

The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.

Reproduce the asset-to-trial workflow with PatSnap MCP

3. Clinical readouts: what is known

A Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of the Safety and Efficacy of SP-624 in the Treatment of Adults With Major Depressive Disorder

Phase 2; n=319; evaluation: Not stated in English source. Reported fields: Change From Baseline to Week 4 in Montgomery Asberg Depression Rating Scale (MADRS) Total Score(LS Mean) = -12.6 Point ; Change From Baseline to Week 4 in Montgomery Asberg Depression Rating Scale (MADRS) Total Score(LS Mean) = -10.8 Point

Arrivo BioVentures Announces Positive Results from qEEG and BNA™ Study of SP-624 on Neural Brain Activity Related to Depression and Cognition

Phase 2/3; n=12; evaluation: Positive. Reported fields: beta power = Subjects showed an increase in beta power, particularly in the frontal-central regions compared to patients taking placebo after a single dose, suggesting enhanced synaptic plasticity and neuronal connectivity. ; beta power = Subjects showed an increase in beta power, particularly in the frontal-central regions compared to patients taking placebo after a single dose, suggesting enhanced synaptic plasticity and neuronal connectivity.

Arrivo BioVentures Announces SP-624 Demonstrated Robust Efficacy in Females With Major Depressive Disorder in Phase 2 Study

Phase 2; n=205; evaluation: Positive. Reported fields: MADRS(vs. placebo) = -3.9 Point ; -

These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.

4. Market and competitive position

Forvisirvat addresses Depressive Disorder, Major. Commercial attractiveness rests on addressable patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Small molecule drug—must demonstrate a benefit large enough to offset class-specific safety and operational costs.

The MCP screen returned 2 matched transaction record(s) under the scope “target-level comparable: SIRT6.” Partner activity is a market-validation signal, but it does not establish net present value.

5. Transaction precedent and economics

Transaction-scope note: No direct asset-specific transaction was returned. The table below shows target-level comparable: SIRT6 records as comparable precedents only.

Date	Transaction	Phase at deal	Disclosed economics
2025-01-06	Université libre de Bruxelles and Genflow Biosciences had agreed to develop GF-1005 to treat Sarcopenia	Preclinical	Financial terms not disclosed
2018-11-05	Immunic enters into a global option and license agreement with Daiichi Sankyo	Preclinical	Financial terms not disclosed

Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.

6. IP and freedom-to-operate screen

The milestone feed surfaced a patent-application signal described as “Compositions and methods for treating joint and bone diseases”. The milestone feed surfaced a patent-application signal described as “Compositions and methods for treating depression in females”. The milestone feed surfaced a patent-application signal described as “Griseofulvin compound”.

The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights.

7. Principal risks and diligence gates

Therapeutic index and off-target toxicity
Resistance biology and biomarker-defined patient selection
Differentiation from established and emerging standards

Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.

8. Final go/no-go memorandum

CONDITIONAL GO